Dupixent Approved for Pediatric CSU in EU
Analysis based on 9 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026
The International — European Commission's approval of Dupixent for young children with chronic spontaneous urticaria is a positive development for Regeneron Pharmaceuticals and Sanofi, as it expands their market reach and potential revenue in the European Union. This regulatory milestone is expected to enhance investor confidence in both companies, given Dupixent's established efficacy and safety profile.
The International — European Commission has approved Dupixent (dupilumab), a medicine jointly developed by Regeneron Pharmaceuticals and Sanofi, for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years. This approval is significant as Dupixent becomes the first targeted medicine for this pediatric population in the European Union, expanding its existing indication for adults and adolescents. The decision was based on data from the LIBERTY-CUPID clinical trial program, which demonstrated Dupixent's effectiveness in reducing urticaria activity, itch, and hives compared to placebo. Key figures like George Yancopoulos of Regeneron Pharmaceuticals and Alyssa Johnsen of Sanofi highlighted the drug's potential to become a new standard of care. Additionally, a supplemental Biologics License Application for Dupixent in the same pediatric group is under review by the United States — Food and Drug Administration, with a decision expected by April 2026, indicating further potential market expansion.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard